Fast Track status enables closer FDA engagement to potentially accelerate development of a CDH6-directed ADC in ...
LTG-001 demonstrated rapid absorption with a Tmax of approximately 1.5 hours. The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain.
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results